Shire launches ADHD tech challenge

Share this article:

Taking a page from Sanofi, Shire is preparing to launch a developer challenge “to create technology driven solutions that aid individuals with ADHD during the transition from adolescence into adulthood.”

The company's two-stage Shire ADHD Transitions Challenge will shower $150,000 in awards on eight teams of developers. The overall winner will take home $100,000 and score two tickets to the Fall 2013 Health 2.0 conference, where their win will be announced.

Judges will be looking for tools that help ADHD patients manage transitions – such as those from high school to the less-structured environment of college life, or from college to the workforce – as well as addressing everyday organizational and life management challenges and encouraging medication adherence. For the first phase of the challenge (submissions are due by March 17), teams will submit a five-page plan. In the second phase, five finalist teams will execute on their plans.  

A 2007 survey suggests that almost 10% of US children and 4.4% of adults are affected by ADHD, for which Shire markets Adderall XR, Intuniv and Vyvanse.

Shire's contest is reminiscent of Sanofi's Data Design Diabetes and Collaborate | Activate challenges, for technology to help diabetes patients and patient advocacy groups, respectively.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.